Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.
Fiche publication
Date publication
décembre 2022
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre, Dr GAIDDON Christian, Dr GROSS Isabelle, Dr GUERIN Eric, Dr JUNG Alain, Dr ROMAIN Benoit, Dr MELLITZER Georg, Dr VENKATASAMY Aina, Dr MIGUET Laurent
Tous les auteurs :
Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G
Lien Pubmed
Résumé
Gastric cancer (GC) is an aggressive disease due to late diagnosis resulting from the lack of easy diagnostic tools, resistances toward immunotherapy (due to low PD-L1 expression), or chemotherapies (due to p53 mutations), and comorbidity factors, notably muscle atrophy. To improve our understanding of this complex pathology, we established patient-derived xenograft (PDX) models and characterized the tumor ecosystem using a morpho-functional approach combining high-resolution imaging with molecular analyses, regarding the expression of relevant therapeutic biomarkers and the presence of muscle atrophy.
Mots clés
Cisplatin, Gastric cancer, Immune checkpoint signaling hypoxia, Magnetic resonance imaging, Mouse models, PD-L1, p53
Référence
Gastric Cancer. 2022 12 19;: